|
KMID : 0964020130130010074
|
|
Journal of the Korean Liver Cancer Study Group
2013 Volume.13 No. 1 p.74 ~ p.79
|
|
|
A Case of Recurred Hepatocellular Carcinoma after Treated by Trans-Arterial Chemoembolization
|
|
Lee Sang-Heun
Kim Mi-Na
Chon Young-Eun
Kim Beom-Kyung
Kim Seung-Up
Park Jun-Yong
Kim Do-Young
Ahn Sang-Hoon
Chon Chae-Yoon
Han Kwang-Hyub
|
|
|
Abstract
|
|
|
|
Hepatocelluar carcinoma (HCC) is the most common primary liver cancer in the world and the most prevalent cancer among patients liver cirrhosis. The management of HCC depends on tumor stage and the degree of liver dysfunction. Patients with intermediate-stage HCC are ineligible for surgical or local ablative treatments. Current treatment guidelines recommend trans-arterial chemoembolization (TACE) for intermediate stage of HCC. However, tumor recurrence after TACE is universal and the survival benefit is relatively small. Hence, new strategies are needed to improve the outcome of HCC patients undergoing TACE. Recently, the combination of target agents with TACE has shown promising overall survival in advanced HCC. It is necessary to investigate new treat strategy how to increase treatment outcome of advanced HCC by new treat strategy.
|
|
|
KEYWORD
|
|
|
Hepatocellular carcinoma, Trans-arterial chemoembolization, Brivanib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|